Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
In a small randomized control study, researchers in Wuhan, China assigned 62 patients with mild illness to either the control group (in which patients could receive supplemental oxygen, unspecified antiviral agents, antibiotic agents, and immune globulin, with or without glucocorticoids) or the experimental group (in which patients also received 400 mg of hydroxychloroquine daily).
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
French open-label non-randomized clinical trial in support of treating COVID-19 patients with HCQ
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
In vitro testing revealed synergistic effect of combined hydroxychloroquine (HCQ) and azithromycin (AZM) on SARS-CoV-2
Learn After
Methods of the Efficacy of Hydroxychloroquine in Patients with COVID-19 Study
Results of the Efficacy of Hydroxychloroquine in Patients with COVID-19 Study
Limitations in the Efficacy of Hydroxychloroquine in Patients with COVID-19 Study
Key Discussion and Conclusion Points from the Efficacy of Hydroxychloroquine in Patients with COVID-19 Study